JY
EDVA

Jeff Yass’s Endovia Health Sciences, Inc. EDVA Stock Holding History

Jeff Yass’s Portfolio EDVA Stock Details EDVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-118
Closed -$26K – 13521
2022
Q3 		$26K Sell
118
-45
-28% -$17.1K ﹤0.01% 12510
2022
Q2 		$78K Sell
163
-186
-53% -$67.2K ﹤0.01% 11692
2022
Q1 		$158K Buy
+349
New +$178K ﹤0.01% 11510

Other funds holding EDVA

LWM
Lifetime Wealth Management Rockwall, Texas $171M AUM
CL
Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jeff Yass's EDVA Position: Q4 2025 in Review

Jeff Yass sold out of Endovia Health Sciences, Inc. (EDVA) in Q4 2025, closing a stake of 3,446 shares — an estimated $32.5K sold.

Jeff Yass first reported a position in EDVA in Q1 2022 and held it in 11 quarters. The position peaked at $250K in Q1 2022. 13 funds tracked by Wall St. Rank hold EDVA as of Q4 2025.

  • Jeff Yass reported no remaining Endovia Health Sciences, Inc. position as of Q4 2025 after selling out during the quarter.
  • Jeff Yass sold 3,446 Endovia Health Sciences, Inc. shares in Q4 2025, an estimated $32.5K.
  • Jeff Yass first reported a position in Endovia Health Sciences, Inc. in Q1 2022 and held it in 11 quarters.
  • Jeff Yass's Endovia Health Sciences, Inc. position peaked at $250K in Q1 2022.
  • 13 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.